Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

@article{Moore2005SequentialMC,
  title={Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.},
  author={Joseph O. Moore and Stephen L. George and Richard K. Dodge and Philip C. Amrein and Bayard L. Powell and Jonathan E Kolitz and Maria R. Baer and Frederick R. Davey and Clara D. Bloomfield and Richard A Larson and Charles A Schiffer},
  journal={Blood},
  year={2005},
  volume={105 9},
  pages={3420-7}
}
The Cancer and Leukemia Group B (CALGB) study 9222 tested the hypothesis that treatment intensification of acute myeloid leukemia (AML) in first remission with multiple chemotherapy agents is superior to high-dose cytarabine (HiDAC) alone. We enrolled 474 patients younger than 60 years old with untreated de novo AML. Daunorubicin and cytarabine resulted in complete remission (CR) in 342 patients (72%), and 309 of these patients were randomized to receive one of 2 different intensification… CONTINUE READING
46 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…